We serve Chemical Name:N-(2-Hydroxyethyl)-2-phenylacetamide CAS:6269-99-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-(2-Hydroxyethyl)-2-phenylacetamide
CAS.NO:6269-99-4
Synonyms:n-(2-hydroxyethyl)-2-phenylacetamide
Molecular Formula:C10H13NO2
Molecular Weight:179.21600
HS Code:2924299090
Physical and Chemical Properties:
Melting point:59-61ºC
Boiling point:418.5ºC at 760 mmHg
Density:1.129g/cm3
Index of Refraction:1.545
PSA:49.33000
Exact Mass:179.09500
LogP:0.72850
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like n-(2-hydroxyethyl)-2-phenylacetamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-(2-hydroxyethyl)-2-phenylacetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-(2-hydroxyethyl)-2-phenylacetamide Use and application,n-(2-hydroxyethyl)-2-phenylacetamide technical grade,usp/ep/jp grade.
Related News: The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. N-(2-Hydroxyethyl)-2-phenylacetamide manufacturer Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. N-(2-Hydroxyethyl)-2-phenylacetamide supplier Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. N-(2-Hydroxyethyl)-2-phenylacetamide vendor Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. N-(2-Hydroxyethyl)-2-phenylacetamide factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.
